On January 10, 2026, a new clinical trial led by Chien Yu Huang was announced, comparing traditional radiofrequency ablation (RFA) of inferior turbinates to a combined approach that includes posterior nasal RFA. This study intends to assess the safety and effectiveness of these techniques in treating chronic rhinitis and related conditions.
What is the study about?
This upcoming clinical trial focuses on evaluating two procedural interventions for chronic rhinitis, a condition characterized by persistent nasal obstruction, inferior turbinate hypertrophy, and rhinorrhea. The innovative approach incorporates posterior nasal RFA alongside traditional RFA of the inferior turbinates.
Clinical context for the trial
Chronic rhinitis, which includes allergic and nonallergic forms, affects millions of individuals globally. Treatment options often aim to reduce nasal obstruction and rhinorrhea by targeting the hypertrophic inferior turbinates. Traditional RFA has been widely used for this purpose, but incorporating posterior nasal RFA may provide enhanced symptom relief.
Noninvasive and minimally invasive procedures like RFA have gained regulatory attention due to their safety profile and potential to meet performance and benefit-risk criteria as outlined in MDR Annex XIV. This trial aligns with the growing interest in novel combination-based medical interventions.
Trial design and methodology
According to the ClinicalTrials.gov record, participants will be divided into two groups. One group will receive traditional RFA for the inferior turbinates, while the other group will undergo the combined treatment incorporating posterior nasal RFA. The trial seeks to determine differences in efficacy, patient-reported outcomes, and adverse event profiles between the two approaches.
This study is currently classified as “Not yet recruiting.” It will be conducted under the sponsorship of Chien Yu Huang using a standardized methodology to ensure reliability in data collection and analysis.
FAQ
1. What is the primary aim of the study?
To evaluate the effectiveness and safety of combining posterior nasal RFA with traditional inferior turbinate RFA for chronic rhinitis treatment.
2. Who is conducting the trial?
The trial is led by Chien Yu Huang.
3. Is enrollment open?
No, the trial is marked “Not yet recruiting.”
4. What conditions are being studied?
The study targets chronic rhinitis, nasal obstruction, rhinorrhea, nonallergic rhinitis, and inferior turbinate hypertrophy.
Conclusion and implications
This upcoming trial highlights the evolving landscape of chronic rhinitis treatments. Both clinical and regulatory teams should monitor its progress to understand the implications for patient care and device innovation. Enhanced treatment modalities could further refine clinical practice and expand device application criteria.
Disclaimer
This article is intended for informational purposes only. It does not constitute legal, regulatory, or clinical advice. Readers should consult relevant professionals for guidance.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07323888?term=medical+device